Australia’s TPG Telecom Deploys MATRIXX Software to Enable Multiple Brands on a Single, Converged Charging Platform
5.5.2021 03:02:00 EEST | Business Wire | Press release
MATRIXX Software, a global leader in 5G monetization for the communications industry, today announced it has partnered with Australia’s TPG Telecom Limited (ASX: TPG). TPG Telecom operates a number of leading mobile and internet brands including Vodafone, TPG, iiNet, AAPT, Internode and Lebara, providing consumers with a comprehensive portfolio of fixed and mobile products in the Australian telecommunications market.
With their 5G rollout progressing full steam ahead across major Australian cities, TPG Telecom is committed to cementing its place as a strong force for its customers. Looking ahead, as 5G becomes mainstream, TPG Telecom is seeking to unlock new opportunities and offerings resulting from the coming explosion of connected devices. With a goal to improve experience today, while laying the foundation for future innovation, TPG Telecom selected the MATRIXX Digital Commerce Platform to build a flexible, agile service capable of delivering real-time innovation to meet ever-shifting consumer demand.
“At TPG Telecom, the investments we make are designed to provide immediate benefit to our customers today, with an eye towards how we can unlock new opportunities, tomorrow,” said Rob James, Group Chief Digital & Information Officer of TPG Telecom. “Delivering improved value for our shareholders is essential for our success and the MATRIXX platform will enable us with the ability to rapidly innovate and experiment with new monetization models across all of our brands.”
Implemented as part of a full digital transformation program, MATRIXX Digital Commerce Platform enables TPG Telecom to be more commercially competitive, while also reducing costs associated with legacy infrastructure.
“We started with the ambition to consolidate multiple mobile rating platforms whilst still operating as Vodafone Hutchison Australia. Having merged with TPG Corporation to form TPG Telecom, using MATRIXX has further enabled us to ensure all our brands have access to a common rating platform. MATRIXX allows us to consolidate and transform 4G and 5G service monetization by moving to a single real-time platform that’s tightly integrated with our network,” said Easwaren Siva, General Manager Strategy & Architecture of TPG Telecom.
With the first phase completed, MATRIXX is now live for Vodafone branded prepaid services. Later phases of the transformation program will see TPG Telecom migrating mobile postpaid rating across their portfolio of brands, in addition to MVNO, wholesale and enable Standalone 5G charging.
“We are thrilled to be able to help bring TPG Telecom’s vision of improved commercial agility and greater customer experience,” said Glo Gordon, MATRIXX CEO. “Helping to transform how TPG Telecom monetizes today, while giving them a powerful and highly configurable monetization platform for their future innovation, speaks to the core of what we do best — empowering our customers, so that they can empower theirs.”
About TPG Telecom
TPG Telecom Limited was formed by the merger of Vodafone Hutchison Australia Pty Limited and TPG Corporation, formerly named TPG Telecom, on 13 July 2020. The merger brought together two highly complementary businesses, creating the leading challenger full-service telecommunications provider in Australia.
About MATRIXX Software
MATRIXX Software is the global leader in 5G monetization for the communications industry. Serving many of the world’s largest operator groups, regional carriers, and emerging digital service providers, MATRIXX delivers a cloud native digital commerce solution that enables unmatched commercial and operational agility. Unifying IT & networks, MATRIXX delivers a network-grade converged charging system (CCS) enabling efficient hyper-scaling of infrastructure to support consumer services, wholesale and enterprise marketplaces. Through its relentless commitment to product excellence and customer success, MATRIXX empowers businesses to harness network assets and business agility to succeed at web scale.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210504005060/en/
Contact information
Jennifer Kyriakakis
mediainquiry@matrixx.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom